Evidence map›Paper›PMID 38750410›Full record

Trial reportBMC cancer2024

Dietary supplement intake in women with breast cancer before and after diagnosis: results from the SUCCESS C trial.

Dagmar Hauner, Anna Mang, Lara Donik, Florian Schederecker, Dorothy Meyer, Brigitte Rack, Wolfgang Janni, Hans Hauner

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in BMC cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Dagmar HaunerInstitute of Nutritional Medicine, Else Kröner Fresenius Center for Nutritional Medicine, TUM School of Medicine and Health, Technical University of Munich, Munich, Germany.
Anna MangInstitute of Nutritional Medicine, Else Kröner Fresenius Center for Nutritional Medicine, TUM School of Medicine and Health, Technical University of Munich, Munich, Germany.
Lara DonikInstitute of Nutritional Medicine, Else Kröner Fresenius Center for Nutritional Medicine, TUM School of Medicine and Health, Technical University of Munich, Munich, Germany.
Florian SchedereckerInstitute of Nutritional Medicine, Else Kröner Fresenius Center for Nutritional Medicine, TUM School of Medicine and Health, Technical University of Munich, Munich, Germany.
Dorothy MeyerInstitute of Nutritional Medicine, Else Kröner Fresenius Center for Nutritional Medicine, TUM School of Medicine and Health, Technical University of Munich, Munich, Germany.
Brigitte RackDepartment of Gynecology and Obstetrics, University Hospital Ulm, Ulm, Germany.
Wolfgang JanniDepartment of Gynecology and Obstetrics, University Hospital Ulm, Ulm, Germany.
Hans HaunerInstitute of Nutritional Medicine, Else Kröner Fresenius Center for Nutritional Medicine, TUM School of Medicine and Health, Technical University of Munich, Munich, Germany. hans.hauner@tum.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere is little evidence that dietary supplements are beneficial for patients with breast cancer; therefore, they are usually not recommended by treatment guidelines. The aim of the present analysis was to assess the prevalence of dietary supplement (DS) intake among women before and after a breast cancer diagnosis.

methodsParticipants in the SUCCESS C lifestyle intervention study, a randomized controlled trial in women with newly diagnosed intermediate- to high-risk breast cancer, completed two questionnaires on dietary supplement intake 24 months (QS1) and 48 months (QS2) after beginning the lifestyle intervention. The study was registered on 12.17.2008 under the EU Clinical Trials Register https://www.clinicaltrialsregister.eu/ , trial registration number: 2008-005453-38. The questionnaires collected data on DS intake during the 5-year period prediagnosis (QS1) and in the period postdiagnosis (QS2). Multivariate logistic regression models were fitted to examine differences in DS intake between the two intervention groups. The groups were then pooled to examine differences in DS use between the prediagnostic and postdiagnostic period.

resultsA total of 320 questionnaires from 58.5% of intervention group completers and 416 questionnaires from 46.6% of low-level intervention group completers were included in the analysis. Overall, 20.2% of all respondents reported taking DS prior to their diagnosis. After a cancer diagnosis, the percentage of women taking DS significantly increased to 56.4% (p for time effect < 0.0001). No differences in DS intake between the intervention groups were observed. Single or combined preparations of vitamins and minerals/trace elements were the most frequently reported supplements. Notably, a 9-fold increase in vitamin D intake was reported postdiagnosis, where the proportion of women increased from 3.8 to 34.5%.

conclusionA 3-fold increase in the reported intake of dietary supplements was seen in women after a breast cancer diagnosis. These observations underscore the need to incorporate patient education surrounding the use of dietary supplements in a treatment care plan, particularly addressing the negligible benefits as well as the potential risks and treatment interactions.

Indexed as

Breast NeoplasmsDietary SupplementsAdultAgedFemaleHumansLife StyleMiddle AgedSurveys and QuestionnairesBreast cancerDietary supplement useExcess intakeInadequate intakeMicronutrients

Identifiers

PMID38750410
PMCPMC11094984

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.